Model List of Essential Medicines

Daclatasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations ◦ Oral > Solid > tablet: 30 mg (as dihydrochloride); 60 mg (as dihydrochloride)	Chronic hepatitis C

Daclatasvir + sofosbuvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations ◦ Oral > Solid > tablet: 60 mg (as dihydrochloride) + 400 mg	Chronic hepatitis C

Dasabuvir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations ◦ Oral > Solid: 250 mg tablet	Chronic hepatitis C

Elbasvir + grazoprevir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations ◦ Oral > Solid: 50 mg + 100 mg	Chronic hepatitis C

Entecavir

Section	Indications
Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors ◦ Oral > Liquid: 0.05 mg per mL ◦ Oral > Solid: 0.5 mg; 1 mg	Chronic hepatitis B

Glecaprevir + pibrentasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations ◦ Oral > Solid: 50 mg + 20 mg granules ◦ Oral > Solid > tablet: 100 mg + 40 mg	Chronic hepatitis C

Ledipasvir + sofosbuvir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations ◦ Oral > Solid: 90 mg + 400 mg tablet	Chronic hepatitis C

Ombitasvir + paritaprevir + ritonavir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations ◦ Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet	Chronic hepatitis C

Pegylated interferon alfa (2a)

Section	Indications
Medicines for hepatitis C > Other antivirals for hepatitis C ◦ Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe	Chronic hepatitis C

Pegylated interferon alfa (2b)

Section	Indications
Medicines for hepatitis C > Other antivirals for hepatitis C ◦ Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe	Chronic hepatitis C

Ravidasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations ◦ Oral > Solid > tablet: 200 mg	Chronic hepatitis C

Ribavirin

Section	Indications
Medicines for hepatitis C > Other antivirals for hepatitis C ◦ Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution ◦ Oral > Solid: 200 mg; 400 mg; 600 mg	Chronic hepatitis C

Simeprevir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations ◦ Oral > Solid: 150 mg	Chronic hepatitis C

Sofosbuvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations ◦ Oral > Solid > tablet: 200 mg; 400 mg ◦ Oral > Solid > granules: 200 mg in sachet	Chronic hepatitis C

Sofosbuvir + velpatasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations ◦ Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg ◦ Oral > Solid > granules: 150 mg + 37.5 mg in sachet; 200 mg + 50 mg in sachet	Chronic hepatitis C

Tenofovir alafenamide

Section	Indications
Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors ◦ Oral > Solid: 25 mg	Chronic hepatitis B

Tenofovir disoproxil fumarate

Section	Indications
Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors ◦ Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)	Chronic hepatitis B